These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 32498573)

  • 1. Incremental cost-effectiveness analysis of tyrosine kinase inhibitors in advanced non-small cell lung cancer with mutations of the epidermal growth factor receptor in Colombia.
    Lasalvia P; Hernández F; Gil-Rojas Y; Rosselli D
    Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):821-827. PubMed ID: 32498573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia.
    Khoo T; Gao L
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):415-423. PubMed ID: 33151783
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
    Aguiar PN; Haaland B; Park W; San Tan P; Del Giglio A; de Lima Lopes G
    JAMA Oncol; 2018 Aug; 4(8):1080-1084. PubMed ID: 29852038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in Canada.
    Ezeife DA; Kirk V; Chew DS; Nixon NA; Lee R; Le LW; Chan KK; Leighl NB
    Lung Cancer; 2018 Nov; 125():1-7. PubMed ID: 30429004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China.
    Cai H; Zhang L; Li N; Chen S; Zheng B; Yang J; Weng L; Liu MB
    Clin Ther; 2019 Feb; 41(2):280-290. PubMed ID: 30639208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong - A cost-effectiveness analysis.
    You JHS; Cho WCS; Ming WK; Li YC; Kwan CK; Au KH; Au JS
    PLoS One; 2021; 16(3):e0247860. PubMed ID: 33647045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore.
    Aziz MIA; Foo WYX; Toh CK; Lim WT; Ng K
    J Med Econ; 2020 Nov; 23(11):1330-1339. PubMed ID: 32886557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer in China.
    Guan H; Liu G; Xie F; Sheng Y; Shi L
    Clin Ther; 2019 Nov; 41(11):2308-2320.e11. PubMed ID: 31607559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of first-line treatments for advanced epidermal growth factor receptor-mutant non-small cell lung cancer patients.
    Li WQ; Li LY; Chai J; Cui JW
    Cancer Med; 2021 Mar; 10(6):1964-1974. PubMed ID: 33626238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer.
    Bertranou E; Bodnar C; Dansk V; Greystoke A; Large S; Dyer M
    J Med Econ; 2018 Feb; 21(2):113-121. PubMed ID: 28880737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of Osimertinib vs Docetaxel-bevacizumab in Third-line Treatment in EGFR T790M Resistance Mutation Advanced Non-Small Cell Lung Cancer in China.
    Rui M; Li H
    Clin Ther; 2020 Nov; 42(11):2159-2170.e6. PubMed ID: 33028495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations.
    Holleman MS; Al MJ; Zaim R; Groen HJM; Uyl-de Groot CA
    Eur J Health Econ; 2020 Feb; 21(1):153-164. PubMed ID: 31541309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of osimertinib plus chemotherapy for patients with EGFR-mutated advanced non-small cell lung cancer.
    Tian W; Niu L; Zhou R; Wang Z; Ning J; Lu R; Shi Y; Tan Z
    Cancer Med; 2024 Aug; 13(16):e70083. PubMed ID: 39206619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
    Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
    Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations.
    Westerink L; Nicolai JLJ; Samuelsen C; Smit HJM; Postmus PE; Griebsch I; Postma MJ
    Eur J Health Econ; 2020 Aug; 21(6):931-943. PubMed ID: 32328874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations.
    Arrieta O; Catalán R; Guzmán-Vazquez S; Barrón F; Lara-Mejía L; Soto-Molina H; Ramos-Ramírez M; Flores-Estrada D; de la Garza J
    BMC Cancer; 2020 Sep; 20(1):829. PubMed ID: 32873256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.
    Liu J; Jin B; Su H; Qu X; Liu Y
    BMC Cancer; 2019 Jul; 19(1):702. PubMed ID: 31315676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer.
    Aguilar-Serra J; Gimeno-Ballester V; Pastor-Clerigues A; Milara J; Trigo-Vicente C; Cortijo J
    Expert Rev Pharmacoecon Outcomes Res; 2022 Jun; 22(4):637-646. PubMed ID: 34602008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M.
    Huang YH; Tseng JS; Hsu KH; Chen KC; Su KY; Yu SL; Chen JJW; Yang TY; Chang GC
    Sci Rep; 2021 Jun; 11(1):12084. PubMed ID: 34103652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osimertinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost-effectiveness analysis.
    Aguilar-Serra J; Gimeno-Ballester V; Pastor-Clerigues A; Milara J; Marti-Bonmati E; Trigo-Vicente C; Alós-Almiñana M; Cortijo J
    J Comp Eff Res; 2019 Aug; 8(11):853-863. PubMed ID: 31478399
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.